Navigation Links
Importance of policy action to help reduce HCV-related deaths across Europe by 2025
Date:3/31/2011

New findings from two modeling studies presented at the International Liver Congress support the call to action from medical experts and patients in relation to the challenge health inequalities represent in the diagnosis and access to HCV treatment.

The first modelling study looks at current treatment practices and available epidemiological data across a number of EU countries (including Belgium, France, Germany, Italy, Spain and the UK), and shows that based on current practice HCV-related morbidity and mortality (linked to liver cancer deaths) will be reduced by 10% over nine years (2012 2021). In addition, the incidence of cirrhosis will also be reduced by 16%. Both results take into consideration variations across countries in screening, diagnosis and treatment standards.

The study also considered HCV progression if 70% of treatment naive patients and all non-responders and relapsers were treated with a protease inhibitor from 2012 onwards (increasing average SVR to 70% and 60.5% in non-responders and treatment-naive genotype 1 patients respectively). Based on this scenario, findings show that the overall HCV-related mortality would decrease by a further 12% over the same period, corresponding to a relative impact of 117% compared to current practice.

Based on these forecasts, experts conclude that the development and implementation of ambitious policy strategies to ensure effective access to diagnosis and treatment alongside the availability of new therapies (such as proteases inhibitors) could have a major impact in further reducing HCV-related mortality in the future.

A second modelling study looked at French health resource allocation and how this may change with the introduction of triple therapy for non-responders in the near future. In France, the data show the number of patients eligible for treatment (treatment-naive and previous non-responders) will increase two to three folds, which equates to an additional 9,900 to 14,300 patients by 2012.

This demonstrates the need to adjust allocation of health resources at national level to meet this demand.

Mark Thursz, EASL's Vice-Secretary commented: "These types of modelling studies are useful in providing us with data to support our policy efforts with political audiences. We have been saying, alongside patients, that the current challenges to managing viral hepatitis effectively are linked to a wide discrepancy in diagnosis and treatment standards across the different Member States. Now we can build a stronger case when discussing the development of effective health strategies within the EU and at Member State level. The good news is that antiviral treatments are being proven to be effective in substantially reducing HCV-related mortality in Europe. We must strengthen our efforts towards a better identification of carriers needing management and treatment."

HCV is a major cause of acute hepatitis and chronic liver disease. Globally, an estimated 130� million people are chronically infected with HCV and 3𔃂 million are newly infected each year.


'/>"/>

Contact: Isabelle Scali
easlpressoffice@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. PDA Reminds Parents About the Importance of Childrens Oral Health
2. Dental Students Learn Importance of Legislative Process to Profession
3. Recent Earthquakes Across the World Underscore the Importance of Emergency Preparedness Supplies and Survival Kits for Individuals, Families and Businesses
4. HCG True Diet – Dr. Robert True Speaks About the Importance of Medical Supervision for HCG Diets
5. Breast cancer screening program should give higher importance to younger women
6. Study evaluates importance of timeliness of care in breast cancer diagnosis and treatment
7. Water Community Stresses Importance of Security During Drinking Water Week
8. Trupanion Emphasizes the Importance of Pet Insurance for Small Pets
9. Preschool depression: The importance of early detection of depression in young children
10. Childhood Obesity Institute Symposium at Children's National Medical Center Zeroes in on the Importance of Multi-Disciplinary Approach to Curb Childhood Obesity
11. ‘Protein Lady' Announces New Blog to Promote Importance of Protein-Rich Diet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that ... Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains ... lens flare and light leak transitions have a very high-dynamic range for super smooth ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a ... has set out for each of his children. “The Angel” is the creation of ... Music in New York City, and impassioned writer. , When asked of her new ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton Healthcare Products ... was featured in a study indicating superior performance against competitive products in secretion ... Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the ...
(Date:1/20/2017)... ... 2017 , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection ... is the creation of published author, Gene Gaapf, a retired truck driver, and a ... have been writing since high school and have many different titles,” Gaapf mentions about ...
(Date:1/19/2017)... ... 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) announced ... Models (APMs) in 2017. Clinicians who participate in APMs are paid for the quality ... the Administration’s effort to build a system that delivers better care and one in ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis instruments and consumables for the medical ... to discuss its financial results for the third quarter ... will be at 4:15 p.m. ET on Thursday, January ... the third quarter fiscal year 2017 after the market ...
(Date:1/19/2017)... , Jan. 19, 2017  Sensus Healthcare, ... device company specializing in the treatment of non-melanoma ... keloids, with superficial radiation therapy, today announced that ... year 2016 financial results on Thursday, February 2, 2017 ... will hold a conference call with the investment ...
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
Breaking Medicine Technology: